Log in to your Inderes Free account to see all free content on this page.
Biotage
140.6
SEK
-0.64 %
Less than 1K followers
BIOT
NASDAQ Stockholm
Medical Equipment & Services
Health Care
Overview
Ownership
Investor consensus
-0.64%
+37.57%
+5.87%
-12.56%
-12.51%
-12.51%
-30.4%
+22.69%
+42.62%
Biotage operates in the biotechnology industry and focuses on the development and manufacture of products for chemical analysis and preparative chromatography. The company's products are aimed at researchers and laboratories in drug development and food analysis. The operations are international and target companies and institutions globally. Biotage was founded in 1987 and is headquartered in Uppsala.
Read moreMarket cap
11.38B SEK
Turnover
224.15M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
16.7.
2025
Interim report Q2'25
23.10.
2025
Interim report Q3'25
19.2.
2026
Annual report '25
All
Webcasts
Press releases
ShowingAll content types
Biotage, Audiocast with teleconference, Q1'25
Biotage AB (publ) Interim report January-March 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Statement by the Board of Directors of Biotage in relation to the public offer from RWK BidCo
Biotage AB (publ) publishes Annual and Sustainability Report 2024
NOTICE OF ANNUAL GENERAL MEETING OF BIOTAGE AB (PUBL)
Biotage, Audiocast with teleconference, Q4'24
Biotage AB (publ) Year end Report January-December 2024
Biotage, Audiocast with teleconference, Q3'24
Biotage AB (publ) Interim report January-September 2024
Biotage appoints Nomination Committee
Change in number of shares and votes
Issue and re-purchase of class C shares for incentive program
Biotage AB appointment of new CEO
Change in number of votes
Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan
Reclassification of class C shares to ordinary shares and transfer of ordinary shares within the framework of a long-term incentive plan
Biotage AB (publ) Interim report January-June 2024
